Dr. Sarah Chen
Hematologist-Oncologist
Academic physician specializing in CLL and other chronic lymphoproliferative disorders. Associate Professor at a major academic medical center. Known for being data-driven and staying current with the latest treatment protocols. Has extensive experience with venetoclax-based combinations and fixed-duration therapy approaches in both first-line and relapsed/refractory settings.
Treatment Preferences
Strong advocate for venetoclax-based fixed-duration combinations in both first-line and relapsed/refractory CLL. Values the potential for treatment-free remission and deep responses. Considers patient comorbidities and genetic markers (TP53, IGHV) in treatment decisions. Prefers treatments with clear monitoring guidelines and predictable side effect profiles.